Marker Therapeutics: Focused on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. MT-401, its lead MultiTAA-specific T cell product candidate, has received Orphan Drug Designation for the treatment of post-transplant acute myeloid leukemia (AML) and is currently in a Ph 2 study (n=160) evaluating clinical efficacy in both the adjuvant (n=120) and active disease (n=40) setting. Topline results from the active disease group is expected in Q1 2022.